Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran

Payandeh, Mehrdad; Najafi, Safa; Shojaiyan, Fateme-Zahra; Sadeghi, Masoud

doi:10.7314/apjcp.2016.17.3.1513

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subgroup analysis results on hematological AEs show that the incidences of thrombocytopenia (RR =0.87, 95% CI: 0.60–1.25, P=0.44) were higher in the RCHOP-14 arm ( 9 , 10 , 12 - 14 ), although this has no statistical significance. One of the subgroup analyses with patients who received RCHOP-21, who have a higher trend of anemia when ceasing treatment Watanabe et al (RR =1.15, 95% CI: 0.88–1.50, P=0.29), was observed ( 14 , 17 , 18 ). The subgroup analysis on non-hematological AEs indicates that patients treated with RCHOP-21 had a higher risk of neurological-related, which was not statistically significant (RR =1.41, 95% CI: 0.85–2.33, P=0.18).…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis

He¹,

Tao²,

Ji³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: With the advent of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) treatment has become considered the appropriate chemotherapy treatment for aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma (NHL). In recent years, RCHOP-14 seems to have achieved better outcomes in patients with aggressive or advanced-stage indolent B-cell NHL than RCHOP-21.Methods: To verify the befitting chemotherapy regimens for patients with B-cell NHL, we searched the electronic databases for relevant English-language literature published in January 2020. The primary outcomes were complete response (CR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Six eligible Phase II and III randomized controlled clinical trials (RCTs) and two high-quality observational comparative studies (OCSs) were extracted, with 5,565 patients with B-cell NHL involved in the evaluation. Results:The analysis demonstrated no significant difference in RCHOP-14 and RCHOP-21 CR rates [odds ratio (OR) =0.98, 95% CI: 0.77-1.24, P=0.85]. Compared with RCHOP-21, the merged hazard ratio (HR) after treatment with RCHOP-14 for PFS and OS was 0.94 (95% CI: 0.84-1.06, P=0.32) and 0.91 (95% CI: 0.83-1.01, P=0.08), respectively. A subgroup analysis based on the international prognostic index (IPI) score showed that both chemotherapy regimens were applicable in B-cell NHL patients with different prognoses.The frequency of toxic side-effects was similar between schemes. Conclusions:The data presented suggest that the efficacy and safety of both regimens are comparable and that RCHOP-14 remains a viable plan in patients with B-cell NHL who prefer a shorter therapy course.

show abstract

Section: Resultsmentioning

confidence: 98%

“…AEs, including both hematological and non-hematological toxicities, with both RCHOP-14 and RCHOP-21 treatment protocols were reviewed in all RCTs. (14,17,18).…”

Section: Treatment-related Toxicitymentioning

confidence: 99%

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis

He¹,

Tao²,

Ji³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…One of subgroup analysis were observed with patients who received RCHOP-21, which has a higher trend to have Anemia when removing to Watanabe et.al. (RR= 1.15, 95% CI 0.88-1.50, P= 0.29 )(14,17,18). The subgroup analysis on non-hematological AEs indicates that Patients treated with RCHOP-21 had a higher risk of neurological-related, which were not statistically signi cant(RR= 1.41, 95% CI 0.85-2.33, P= 0.18 ).…”

mentioning

confidence: 91%

Therapy with of RCHOP-14 Versus RCHOP-21 for People With Aggressive or Advanced Stage Indolent B-Cell Non-Hodgkins Lymphoma: A Systematic Review and Meta-Analysis

He¹,

Tao²,

Ji³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: With the advent of rituximab, RCHOP is considered the appropriate chemotherapy for aggressive or advanced stage indolent B-cell Non-Hodgkins Lymphoma(NHL). RCHOP-14 seems to achieve better outcomes than RCHOP -21 in aggressive or advanced stage indolent B-cell NHL patients in recent years.Methods: To verify the befitting chemotherapy regimens for B-cell NHL patients, we searched the electronic databases for relevant English-language literature published through January 2020. The primary outcomes were complete response(CR),progression-free survival (PFS), overall survival(OS), and Adverse events (AEs). Six eligible Phase II and III clinical randomized controlled trials (RCTs) and two high-quality observational comparative studies (OCSs)were extracted, and 5565 B-cell NHL patients involved in evaluable.Results: The analysis demonstrated no significant difference for CR rate (OR= 0.98,95%CI 0.77-1.24，P=0.85)between RCHOP-14 and RCHOP-21. Compared with RCHOP-21, the merged hazard ratio (HR) for PFS and OS was, respectively, 0.94 (95% CI: 0.84-1.06, P=0.32) and 0.91(95% CI: 0.83-1.01, P= 0.08) after treatment with RCHOP-14.A subgroup analysis based on the international prognostic index(IPI) score showed that both chemotherapy regimens were applicable in B-cell NHL patients with different prognosis. The frequency of toxic side-effects was similar between schemes.Conclusions: Therefore, the data presented suggest that the efficacy and safety of both regimens are comparable and that R-CHOP14 remains a viable plan in B-cell NHL patients who prefer a shorter therapy course.

show abstract

Efficacy and Side Effects of R-Chop Regimen in Patients With Diffuse Large B-Cell Cd20 Positive Lymphoma at Hue University of Medicine and Pharmacy Hospital

Trong

Duy

Viet

et al. 2018

JMP

View full text Add to dashboard Cite

Background: Non-Hodgkin lymphomas (NHL) ranks 10 among the top 15 common cancers worldwide. Diffuse large B-cell lymphoma (DLBCL) is the most common type of the disease. Despite malignancy, DLBCL is curable and sensitive to chemotherapy and radiation therapy. Since first published in 1997, the protocol R-CHOP, a combination of classical chemotherapy CHOP with rituximab, has increased significantly the rate of complete response (CR) and improved overall survival (OS). However, there has been no report of R-CHOP treatment in Hue. Purpose of this research is to evaluate the efficiency of R-CHOP treatment (complete response, progression-free survival) and to describe the toxicities of the protocol. Methods: A retrospective cohort study on 36 patients with diffuse large B-cell lymphoma, CD 20 positive treated with R-CHOP at Hue University Hospital between 2011 and 2016. Results: According to the International prognostic index (IPI), 15 patients (41.7%) had low-risk disease, 14 (38.9%) low-to-intermediate risk, 6 (16.7%) high-to-intermediate risk and 1 (2.7%) high-risk disease. After finishing 8 cycles of therapy, 19 patients (52.8%) achieved complete response. Grade III anemia was observed (13.9%), grade III neutropeniain 4 patients (11.1%) and nausea (5.6%). During a 5-year period, progression – free survival was reported for 66.7% of patients and median for survival time was 3.3 years. Conclusions: The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs progression -free survival in patients with diffuse large-B-cell lymphoma. The treatment of R-CHOP is well tolerated that the adverse events are mostly reported at grade III and able to control effectively. Key words: diffuse large B-cell, non-hodgkin lymphoma, CD20 positive, CHOP, rituximab

show abstract

Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran

Cited by 3 publications

References 21 publications

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis

Therapy with of RCHOP-14 Versus RCHOP-21 for People With Aggressive or Advanced Stage Indolent B-Cell Non-Hodgkins Lymphoma: A Systematic Review and Meta-Analysis

Efficacy and Side Effects of R-Chop Regimen in Patients With Diffuse Large B-Cell Cd20 Positive Lymphoma at Hue University of Medicine and Pharmacy Hospital

Contact Info

Product

Resources

About